Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (274)	2/3/1998 11:01:00 PM
From: Steven Yang	Read Replies (1) \| Respond to of 328

To ALL: Does anyone know when NXTR is going to release its 97Q4 result? The company's fundamental is fine, with two drug in the market, MK on Phase II clinic trial, more experience/expertise in SELEX and parallel SELEX technology, and now specialty chemistry group capitalizing its PASS technology and newly acquired pattend. On the other hand, it is very puzzling to see the price decline and the large short interest. (Do we have any confirmation that the large short position is due to the hedging from the convertable holders, as suggested earlier on this thread?) Steven